Beta Bionics, Inc. Class Action Lawsuit

U.S. Securities Litigation

Beta Bionics Class Action Lawsuit Allegations

The Beta Bionics class action lawsuit asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Beta Bionics common stock. The class action is pending in the U.S. District Court for the Central District of California. It is captioned *Holtzman v. Beta Bionics, Inc.*, No. 26-cv-9999.

If you lost money on your Beta Bionics investment, you are encouraged to submit your information using the form on this page. You may also email adam@bfalaw.com or call 212.789.3619.

Why is Beta Bionics Being Sued for Securities Fraud?

Beta Bionics is a commercial-stage medical device company that offers an automated insulin delivery system for the treatment of diabetes, known as the iLet Bionic Pancreas insulin pump ("iLet"), launched in 2023. The iLet is an insulin delivery system for treatment of diabetes types 1 and 2 that purports to be fully autonomous, determining 100% of insulin doses without manual carbohydrate counting or correction calculations by the user.

The complaint alleges that Beta Bionics falsely touted "the superior clinical outcomes of the iLet" and that healthcare professionals "are seeing good results from their patients and becoming more comfortable prescribing the iLet."

However, the complaint alleges that in June 2025, the FDA issued Beta Bionics a Form 483 detailing more than 18,000 unreported complaints from iLet users since its launch. The complaints concerned, allegedly, cases of life-threatening hypoglycemia due to iLet's aggressive insulin dosing algorithm which Beta Biotics failed to investigate or take corrective actions to address. When Beta Bionics disclosed the Form 483, the complaint alleges the company downplayed the FDA's concerns, claiming that "[t]he Form 483 is primarily related to our customer complaint handling system and our criteria for reporting complaints to the FDA[.]"

Why did Beta Bionics' Stock Drop?

On January 8, 2026, after hours, Beta Bionics announced that a key business metric—the number of new patients starting iLet treatment, or "new patient starts"—had missed analyst estimates by nearly 10%. As alleged, this news caused the price of Beta Bionics stock to decline by $11.85 per share, or 37%, from a closing price of $31.99 per share on January 8, 2026 to a closing price of $20.14 per share on January 9, 2026.

Then, on February 24, 2026, the FDA publicly released a 10-page warning letter, which it had previously sent to Beta Bionics, stating that the company failed to report instances of hypoglycemia caused by iLet malfunctions. As alleged, this news caused the price of Beta Bionics stock to decline by $0.66, or 4.9%, from a closing price of $13.55 per share on February 24, 2026 to a closing price of $12.89 per share on February 25, 2026.

Beta Bionics ($BBNX) Stock Chart



Image Caption: NASDAQ online chart showing Beta Bionics' stock drop following the alleged corrective disclosures.

What is the Beta Bionics Lead Plaintiff Deadline?

You may ask the Court no later than November 3, 2026, to appoint you as Lead Plaintiff through counsel of your choice.

To be a member of the Class, you need not take any action at this time. The ability to share in any potential future recovery is not dependent on serving as Lead Plaintiff.

How Do I Submit My Information?

If you lost money when Beta Bionics securities dropped in price, you are encouraged to submit your information using the form on this page to speak with an attorney about your rights.

You can also contact:

Adam McCall
amccall@bfalaw.com
212.789.3619

All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of any class action lawsuit. The firm will seek court approval for any potential fees and expenses.

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by *Chambers USA*, *The Legal 500*, and *ISS SCAS*, and its attorneys have been named "Elite Trial Lawyers" by the *National Law Journal*, "Litigation Stars" by *Benchmark Litigation*, among the top "500 Leading Plaintiff Financial Lawyers" by *Lawdragon*, "Titans of the Plaintiffs' Bar" by *Law360*, and "SuperLawyers" by *Thomson Reuters*.

Most recently, *The Legal 500* awarded BFA the most client satisfaction accolades of any plaintiff's securities litigation law firm, with clients noting: "[t]here is no better service provider in the practice area," "[t]he interest of the client is always front and center," and "[t]here isn't a better firm in this space." One testimonial described the firm as "nimble and entrepreneurial," with a "relentless focus on adding value for clients."

BFA's notable successes include a recovery of over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

Attorney advertising. Past results do not guarantee future outcomes.